First Tracks Biotherapeutics (TRAX) Income Statement: Revenue & Earnings

First Tracks Biotherapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

First Tracks Biotherapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023
Period Ending	Dec 2025	Dec 2024	Dec 2023
Revenue & Gross Profit
Revenue	0.00	0.00	0.00
Cost of Revenue	139.61	152.35	0.00
Gross Profit	-139.61	-152.35	0.00
Operating Expenses
Research & Development	0.00	152.35	90.26
Selling, General & Administrative	39.39	28.76	20.87
Operating Expenses	39.39	28.76	111.12
Operating Income	-179.01	-181.10	-111.12
Other Income/Expense
Interest Income	12.94	17.38	12.31
Interest Expense	0.00	0.00	0.00
Other Income/Expense	-0.02	0.01	0.00
Income
Income Before Tax	-166.09	-163.71	-106.15
Income Tax Expense	0.00	0.00	0.00
Net Income	-166.09	-163.71	-106.15
Net Income - Continuous Operations	0.00	-163.71	-106.15
Net Income - Discontinued Operations	0.00	0.00	0.00
EBITDA	-178.45	-180.50	-110.47
EBIT	-179.01	-181.10	-111.12
Depreciation & Amortization	0.56	0.61	0.65
Earnings Per Share
Basic EPS	-	-	-3.00
Diluted EPS	-	-	-3.00
Basic Shares Outstanding	0.00	0.00	34.75
Diluted Shares Outstanding	0.00	0.00	34.75